Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Gonzalo Recondo, Linda Mahjoubi, Aline Maillard, Yohann Loriot, Ludovic Bigot, Francesco Facchinetti, Rastislav Bahleda, Anas Gazzah, Antoine Hollebecque, Laura Mezquita, David Planchard, Charles Naltet, Pernelle Lavaud, Ludovic Lacroix, Catherine Richon, Aurelie Abou Lovergne, Thierry De Baere, Lambros Tselikas, Olivier Deas, Claudio NicotraMaud Ngo-Camus, Rosa L. Frias, Eric Solary, Eric Angevin, Alexander Eggermont, Ken A. Olaussen, Gilles Vassal, Stefan Michiels, Fabrice Andre, Jean Yves Scoazec, Christophe Massard, Jean Charles Soria, Benjamin Besse, Luc Friboulet

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

7 Citaten (Scopus)

Samenvatting

Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole exome sequencing. In total, 163 tumours were implanted in NOD scid gamma (NSG) or nude mice and 54 patient-derived xenograft (PDX) models were established, with a success rate of 33%. Adverse events secondary to invasive tumour sampling occurred in 24 patients (7.6%). Study recruitment is still ongoing. Systematic molecular profiling of tumours and the development of patient-derived models of acquired resistance to targeted agents and immunotherapy is feasible and can drive the selection of the next therapeutic strategy.

Originele taal-2Engels
Artikelnummer27
Tijdschriftnpj Precision Oncology
Volume4
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - 1 dec. 2020
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit